Drugs / I-124-CLR1404
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01898273 | Feb 2014 → Sep 2015 | glioblastoma | Cellectar Biosciences, Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | I-124-CLR1404 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01898273 ↗ |
| Route | Intravenous | “single-dose, intravenous” NCT01898273 ↗ |